Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 13, 2026Clinical and Experimental NephrologyOpen Access

Roxadustat and incidence of peritoneal dialysis-associated peritonitis: a propensity score–matched cohort study

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Overview

Randomized trial investigates Roxadustat's role in lowering peritoneal dialysis-associated peritonitis risk, suggesting protective effects beyond anemia correction.

Key Points

  • This study aims to determine whether Roxadustat reduces the incidence of peritoneal dialysis-associated peritonitis compared to rhuEPO.
  • Propensity score matching was performed based on age, sex, and clinical parameters.
  • Patients treated with Roxadustat or rhuEPO were enrolled for at least three months.
  • The primary outcome was peritonitis incidence rate calculated as episodes per person-year.
  • Roxadustat group had 0.131 peritonitis episodes per patient-year versus 0.212 in the rhuEPO group.
  • Adjusted incidence rate ratio for Roxadustat vs rhuEPO was 0.494 (95% CI 0.252-0.970; p = 0.041).
  • The findings indicate that Roxadustat is associated with significantly reduced PDAP risk.

Cite This Study

A 2026 study studied this question.

synapsesocial.com/papers/6a7d75d82b0e0cff3f63eadbhttps://doi.org/10.1007/s10157-026-02926-6
View Full Paper
Ask AI
Bookmark
Share